Business Context and Reporting Period
Company: Theravance Biopharma, Inc. (TBPH)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: A biopharmaceutical company focused on the development and commercialization of medicines, primarily YUPELRI (revefenacin) for COPD. The company operates in a single segment and is incorporated in the Cayman Islands with tax residency in Ireland.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $107.5 million | $64.4 million |
| Net Income (Loss) | $105.9 million | ($56.4 million) |
| Operating Expenses | $111.1 million | $111.3 million |
| Cash, Cash Equivalents & Marketable Securities | $326.5 million | $88.3 million |
| Net Cash Provided by Operating Activities | $238.5 million | ($11.5 million) |
| Long-Term Debt | $0 | $0 |
Note: 2025 Net Income was significantly driven by non-recurring gains from the sale of royalty assets and milestone payments.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 67% to $107.5 million, driven by a 16% increase in collaboration revenue from YUPELRI and $32.5 million in new licensing and milestone revenue.
- Profitability Shift: The company moved from a net loss of $56.4 million in 2024 to a net income of $105.9 million in 2025. This turnaround was primarily due to a $75.1 million net gain on the sale of TRELEGY royalty assets and $50.0 million in TRELEGY milestone income.
- Asset Sale: In June 2025, the company sold its remaining royalty interest in TRELEGY to GSK plc for $225.0 million, retaining rights to up to $150.0 million in future milestone payments.
- YUPELRI Performance: Total YUPELRI net sales (100% recorded by partner Viatris) grew 12% to $266.6 million. The company received a $25.0 million milestone payment in January 2026 for achieving $250.0 million in US net sales in 2025.
Guidance, Outlook, and Risks
Strategic Review and Restructuring
Following the failure of the ampreloxetine Phase 3 (CYPRESS) study to meet its primary endpoint in March 2026, the Board's Strategic Review Committee is accelerating its evaluation of alternatives to maximize shareholder value, including a potential sale of the company. Concurrently, the company is implementing an organizational restructuring to wind down its R&D function and reduce G&A, targeting a 60% reduction in operating expenses (approx. $70 million run-rate savings) starting in Q3 2026.
Outlook
- Liquidity: As of December 31, 2025, the company held $326.5 million in cash and investments. With recent milestone receipts in early 2026, management expects cash resources to exceed $400 million by the end of Q1 2026, sufficient to fund operations for at least 12 months.
- TRELEGY Milestones: The company is eligible to receive up to $100.0 million in remaining milestone payments from Royalty Pharma based on 2026 TRELEGY global net sales.
Risks and Contingencies
- Clinical Failure: The ampreloxetine program is being wound down after failing to meet its primary endpoint in the CYPRESS study.
- Generic Competition: Litigation regarding YUPELRI patents has been settled with most generic applicants, granting them a royalty-free license to launch in the US on or after April 23, 2039. Litigation with one remaining generic company (Mankind Pharma) is pending, with an agreement to delay market entry until after August 25, 2031.
- Strategic Uncertainty: The ongoing strategic review process may result in a transaction, but there is no assurance of a successful outcome.
Key Facts for Investor Verification
- Non-Recurring Income: Verify the sustainability of the 2025 net income, which was heavily influenced by the one-time $75.1 million gain on the sale of TRELEGY royalties and milestone payments.
- Restructuring Costs: Monitor the execution of the announced restructuring, which includes winding down R&D and incurring $5.0 million to $7.0 million in one-time severance costs.
- Strategic Alternatives: Track the progress of the Strategic Review Committee's evaluation of a potential sale of the company.
- Patent Expirations: Confirm the timeline for generic entry of YUPELRI, currently set for April 2039 for settled parties and August 2031 for the remaining litigant.
- Cash Runway: Assess the company's ability to maintain operations post-restructuring without additional capital raises, given the wind-down of the ampreloxetine program.